6-(2-bromo-2-methylpropanoyl)-2H-1,4-benzoxazin-3(4H)-one | 943993-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-(2-bromo-2-methylpropanoyl)-2H-1,4-benzoxazin-3(4H)-one
• 英文别名: 6-(2-bromo-2-methylpropanoyl)-4H-1,4-benzoxazin-3-one
• CAS: 943993-91-7
• 化学式: C₁₂H₁₂BrNO₃
• 分子量: 298.136
• InChiKey: AVHFAGUUAOUFAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2-bromo-2-methylpropanoyl)-2H-1,4-benzoxazin-3(4H)-one 、 4-氨基-5-甲基-4H-3-巯基-1,2,4-三唑 在 乙酸乙酯 、 碳酸氢钠 、 magnesium sulfate 、 甲醇 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 24.0h， 以to give the title compound (0.40 g)的产率得到6-(3,7,7-trimethyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)-2H-1,4-benzoxazin-3(4H)-one
  参考文献：
  名称：

  Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands

  摘要：

  本发明涉及其中每个符号如规范所定义的化合物，该化合物具有优越的矿物质皮质激素受体拮抗作用，可作为预防或治疗高血压、心力衰竭等药物，包括具有融合杂环的化合物、其前药或其盐；以及预防或治疗高血压、心力衰竭等疾病的药剂。

  公开号：

  US20090253687A1
• 作为产物：
  描述：

  2H-1,4-苯并噁嗪-3(4H)-酮 在 aluminum (III) chloride 、 pyridinium hydrobromide perbromide 、 氢溴酸 作用下， 以 溶剂黄146 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 6-(2-bromo-2-methylpropanoyl)-2H-1,4-benzoxazin-3(4H)-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists

  摘要：

  Dihydrofuran-2-one and dihydropyrrol-2-one derivatives were identified as novel, potent and selective mineralocorticoid receptor (MR) antagonists by the structure-based drug design approach utilizing the crystal structure of MR/compound complex. Introduction of lipophilic substituents directed toward the unfilled spaces of the MR and identification of a new scaffold, dihydropyrrol-2-one ring, led to potent in vitro activity. Among the synthesized compounds, dihydropyrrol-2-one 11i showed an excellent in vitro activity (MR binding IC50 = 43 nM) and high selectivity over closely related steroid receptors such as the androgen receptor (AR), progesterone receptor (PR) and glucocorticoid receptor (GR) (>200-fold for AR and PR, 100-fold for GR). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.07.043

文献信息

• WO2007/77961
  申请人：——

  公开号：——

  公开（公告）日：——
• FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1971596A2

  公开（公告）日：2008-09-24
• [EN] FUSED HETEROCYCLIC COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE FUSIONNÉ ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2007077961A2

  公开（公告）日：2007-07-12

  [EN] The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.
  [FR] La présente invention concerne un composé de formule (Ia), dans laquelle chaque symbole est tel que défini dans la description. Ce composé présente une action antagoniste vis-à-vis des récepteurs des corticoïdes et est utile comme agent pour la prévention ou le traitement de l'hypertension, de l'insuffisance cardiaque et analogue. L'invention concerne également un composé comprenant un hétérocycle fusionné, ou un promédicament ou un sel de celui-ci, ainsi qu'un agent pour la prévention ou le traitement de l'hypertension, de l'insuffisance cardiaque et analogue.
• Design, synthesis, and structure–activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists
  作者：Tomoaki Hasui、Taiichi Ohra、Norio Ohyabu、Kouhei Asano、Hideki Matsui、Atsushi Mizukami、Noriyuki Habuka、Satoshi Sogabe、Satoshi Endo、Christopher S. Siedem、Tony P. Tang、Cassandra Gauthier、Lisa A. De Meese、Steven A. Boyd、Shoji Fukumoto

  DOI：10.1016/j.bmc.2013.07.043

  日期：2013.10

  Dihydrofuran-2-one and dihydropyrrol-2-one derivatives were identified as novel, potent and selective mineralocorticoid receptor (MR) antagonists by the structure-based drug design approach utilizing the crystal structure of MR/compound complex. Introduction of lipophilic substituents directed toward the unfilled spaces of the MR and identification of a new scaffold, dihydropyrrol-2-one ring, led to potent in vitro activity. Among the synthesized compounds, dihydropyrrol-2-one 11i showed an excellent in vitro activity (MR binding IC50 = 43 nM) and high selectivity over closely related steroid receptors such as the androgen receptor (AR), progesterone receptor (PR) and glucocorticoid receptor (GR) (>200-fold for AR and PR, 100-fold for GR). (C) 2013 Elsevier Ltd. All rights reserved.
• Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
  申请人：Fukumoto Shoji

  公开号：US20090253687A1

  公开（公告）日：2009-10-08

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

  本发明涉及其中每个符号如规范所定义的化合物，该化合物具有优越的矿物质皮质激素受体拮抗作用，可作为预防或治疗高血压、心力衰竭等药物，包括具有融合杂环的化合物、其前药或其盐；以及预防或治疗高血压、心力衰竭等疾病的药剂。